«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

24卷

期数:

2018年01期

页码:

36-39

栏目:

临床医学

出版日期:

2018-01-20

文章信息/Info

Title:

Expression of β-catenin in non-specific invasive ductal carcinoma and its effect on prognosis

文章编号:

1006-8147(2018)01-0036-04

作者:

杨丽敏; 秦凤霞; 黄 勇; 马勇杰

（天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，乳腺癌防治教育部重点实验室，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津300060）

Author(s):

YANG Li-min; QIN Feng-xia; HUANG Yong; MA Yong-jie

（Cancer Institute and Hospital，Tianjin Medical University, National Clinical Research Center for Cancer，Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of Education，Key Laboratory of Cancer Prevention and Therapy, Tianjin，Tianjin’s Clinical Research Center for Cancer，Tianjin 300060, China）

关键词:

非特殊型浸润性导管癌; β-catenin; 雌激素受体; 生存

Keywords:

invasive ductal carcinoma;  not otherwise; β-catenin; ER; prognosis

分类号:

R737.9

DOI:

-

文献标志码:

A

摘要:

目的：探讨β-catenin在非特殊型浸润性导管癌（IDC-NOS）中的表达情况及其与患者临床病理参数、预后的关系。方法：采用免疫组织化学染色技术检测273例IDC-NOS中β-catenin的表达情况，分析β-catenin与IDC-NOS患者临床病理参数以及生存之间的关系。结果：β-catenin的异常表达与雌激素受体状态（ER）显著负相关（r_s=-0.134，P=0.027），与其他病理学参数均不相关。β-catenin异常表达的IDC-NOS患者预后差。在ER阳性的IDC-NOS患者中，β-catenin异常表达的患者预后差；在ER阴性的IDC-NOS患者中，β-catenin的表达对患者预后没有影响。结论：β-catenin异常表达的IDC-NOS患者预后差。β-catenin的异常表达与ER状态呈显著负相关。β-catenin的表达情况能够影响ER阳性IDC-NOS患者的预后。

Abstract:

Objective: To explore the expression of β-catenin in IDC-NOS (Invasive ductal carcinoma, not otherwise specified) tissues and its relationship with the clinicopathologic parameters and prognosis of this tumor. Methods: The expression of β-catenin in 273 cases of IDC-NOS was detected by immunohistochemical method, and the correlation between β-catenin and pathological features of IDC-NOS was analyzed. Results: The aberrant expression of β-catenin was negatively correlated with estrogen receptor (ER) status（r_s=-0.134，P=0.027）, and uncorrelated with other clinicopathologic parameters. The aberrant expression of β-catenin was associated with poor prognosis. Moreover, the aberrant expression of β-catenin could not indicate poor prognosis in ER negative patients but could indicate poor prognosis in ER positive patients. Conclusion: Aberrent expression of β-catenin in IDC-NOS patients may indicate poor prognosis. The aberrant expression of β-catenin was negatively correlated with ER status. In the presence of ER, the aberrant expression of β-catenin could indicate poor prognosis of IDC-NOS patients.

参考文献/References:

[1] Hammond M E, Hayes D F, Wolff A C, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Oncol Pract, 2010, 6(4): 195
[2] Harvey J M, Clark G M, Osborne C K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer [J]. J Clin Oncol, 1999, 17(5): 1474
[3] Katuri V, Tang Y, Li C, et al. Critical interactions between TGF-beta signaling/ELF, and E-cadherin/beta-catenin mediated tumor suppression [J]. Oncogene, 2006, 25(13): 1871
[4] Varisli L, Ozturk B E, Akyuz G K, et al. HN1 negatively influences the beta-catenin/E-cadherin interaction, and contributes to migration in prostate cells [J]. J Cell Biochem, 2015, 116(1): 170
[5] Uematsu K, Kanazawa S, You L, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin [J]. Cancer Res, 2003, 63(15): 4547
[6] Li H, Kim J H, Koh S S, et al. Synergistic effects of coactivators GRIP1 and beta-catenin on gene activation: cross-talk between androgen receptor and Wnt signaling pathways [J]. J Biol Chem, 2004, 279(6): 4212
[7] Parr C, Mirzaei N, Christian M, et al. Activation of the Wnt/beta-catenin pathway represses the transcription of the beta-amyloid precursor protein cleaving enzyme (BACE1) via binding of T-cell factor-4 to BACE1 promoter [J]. FASEB J, 2015, 29(2): 623
[8] Raurell I, Castano J, Franci C, et al. Presenilin-1 interacts with plakoglobin and enhances plakoglobin-Tcf-4 association. Implications for the regulation of beta-catenin/Tcf-4-dependent transcription [J]. J Biol Chem, 2006, 281(3): 1401
[9] Asally M, Yoneda Y. Beta-catenin can act as a nuclear import receptor for its partner transcription factor, lymphocyte enhancer factor-1 (lef-1) [J]. Exp Cell Res, 2005, 308(2): 357
[10] Prosperi J R, Goss K H. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer [J]. Curr Drug Targets, 2010, 11(9): 1074
[11] Li S, Li S, Sun Y, et al. The expression of beta-catenin in different subtypes of breast cancer and its clinical significance [J]. Tumour Biol, 2014, 35(8): 7693
[12] Lopez-Knowles E, Zardawi S J, McNeil C M, et al. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients [J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(1): 301
[13] Pang H, Lu H, Song H, et al. Prognostic values of osteopontin-c, E-cadherin and beta-catenin in breast cancer [J]. Cancer Epidemiol, 2013, 37(6): 985
[14] Zhang D P, Li X W, Lang J H. Prognostic value of beta-catenin expression in breast cancer patients: a meta-analysis [J]. Asian Pac J Cancer Prev, 2015, 16(14): 5625
[15] Gupta N, Schmitt F, Grebhardt S, et al. Beta-catenin is a positive regulator of estrogen receptor-alpha function in breast cancer cells [J]. Cancers (Basel), 2011, 3(3): 2990

相似文献/References:

[1]范 丹,宋文静,张艳辉,等.PRRX1的表达对卵巢癌血管生成拟态形成及患者预后的影响[J].天津医科大学学报,2018,24(01):1.
　FAN Dan,SONG Wen-jing,ZHANG Yan-hui,et al.Effect of PRRX1 expression on VM formation and prognosis in ovarian cancer[J].Journal of Tianjin Medical University,2018,24(01):1.

备注/Memo

备注/Memo:

作者简介 杨丽敏（1991-），女，硕士在读，研究方向：乳腺癌的发生发展与化疗耐药的机制；通信作者：马勇杰，E-mail: yongjiemagu@aliyun.com。

常用功能

更新日期/Last Update: 2018-01-19